ANUSOL HC SUMMARY
(Hydrocortisone Cream, USP)
The topical corticosteroids constitute a class of primarily synthetic steroids used as antiinflammatory and antipruritic agents. Anusol-HC 2.5% (Hydrocortisone Cream, USP) is a topical corticosteroid with hydrocortisone 2.5% (active ingredient) in a water-washable cream containing the following inactive ingredients: benzyl alcohol, petrolatum, stearyl alcohol, propylene glycol, isopropyl myristate, polyoxyl 40 stearate, carbomer 934, sodium lauryl sulfate, edetate disodium, sodium hydroxide to adjust the pH, and purified water.
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Published Studies Related to Anusol HC (Hydrocortisone Topical)
Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in
children: a randomized clinical trial. 
IMPORTANCE: Alopecia areata is an idiopathic cause of hair loss with limited
therapeutic repertoire. OBJECTIVE: To compare the efficacy and safety of a high- vs low-potency topical
corticosteroid in pediatric patients...
Randomized, double-blind, split-side, comparison study of moisturizer containing
licochalcone A and 1% hydrocortisone in the treatment of childhood atopic
CONCLUSION: Lic A had a similar result in terms of SCORAD compared to 1%
Randomized, double-blind, split-side comparison study of moisturizer containing
licochalcone vs. 1% hydrocortisone in the treatment of infantile seborrhoeic
hydrocortisone for the treatment of ISD... CONCLUSION: Moisturizer containing 0.025% licochalcone had higher cure rate
Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. [2011.11.17]
BACKGROUND: Tacrolimus is a topical calcineurin inhibitor with immunomodulatory, anti-inflammatory, and fungicidal properties that may be beneficial in the treatment of facial seborrheic dermatitis. OBJECTIVES: We sought to compare the efficacy and safety of tacrolimus with standard corticosteroid treatment in adults with facial seborrheic dermatitis in a phase II, single-blind, randomized controlled trial... CONCLUSION: Tacrolimus 0.1% ointment required significantly fewer applications compared with hydrocortisone 1% ointment to achieve a comparable clinical response in adults with facial seborrheic dermatitis. Tacrolimus was generally well tolerated. Copyright (c) 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis. [2011.07.01]
This study compared the efficacy of a 0.0584% hydrocortisone aceponate (HCA) spray (Cortavance((R)) ; Virbac SA) and ciclosporin (Atopica((R)) ; Novartis Animal Health) in canine atopic dermatitis in a single-blind randomized controlled trial. Dogs received HCA (two sprays/100 cm(2) ; n = 24) or ciclosporin (5 mg/kg; n = 21)...
Clinical Trials Related to Anusol HC (Hydrocortisone Topical)
The Safety of Proctofoam-HC in the Third Trimester of Pregnancy [Recruiting]
Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis [Recruiting]
Efficacy Study of Low-Dose Hydrocortisone Treatment for Fibromyalgia [Completed]
This study is based on clinical findings that some patients with fibromyalgia have a tendency
towards lower levels of the stress hormone cortisol. The hypothesis to be tested in this
study is that the administration of a very low-dose of cortisol which has no side effects
corrects this deficiency and results in an improvement of symptoms
Metabolic Effects of Acute Cortisol Withdrawal in Adrenal Failure [Completed]
Effects of adrenal steroids is generelly drawn from studies of hypercortisolism. The effects
of physiological cortisol substitution and withdrawal is studied and related to the clinical
syndrome of adrenal insufficiency.
Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants [Recruiting]
The purpose of this study is to investigate the early use of hydrocortisone in hypotensive
very low birth weight infants.
Based on the observations that:
- hypotension is a common problem in very low birthweight infants and is associated with
brain injury and poor neurological outcomes;
- some infants are refractory to standard treatment (volume expansion and vasopressors),
which is not exempt of adverse effects;
- relative adrenal insufficiency has been described in this population; we hypothesize
that hydrocortisone is effective in the treatment of hypotension in this population and
reduce the need for vasopressors.